| Message: | https://www.sarmshgpharm.com/company-news/gw501516%ef%bc%88cardarine%ef%bc%89%ef%bc%9awhat-you-must-know-before-use-it%ef%bc%9f/
GW501516, also known as Cardarine, is a PPARδ receptor agonist discovered in the 1990s. It was originally developed to treat obesity, diabetes and cardiovascular disease. But as research continues to deepen, GW501516 has gradually become one of the most popular fat-reducing SARMs. It is a selective agonist of the PPARδ receptor with high affinity for PPARδ. In rats treated with GW501516, increased fatty acid metabolism in skeletal muscle and protection against diet-induced obesity and type II diabetes were observed. In rhesus monkey experiments, GW501516 increased high-density lipoprotein (HDL) and decreased low-density lipoprotein (LDL).
GW501516 (Cardarine) mode of action
Bodybuilders significantly improved blood cholesterol levels after using GW501516 (Cardarine), a drug that stimulates the expression of genes involved in glucose and fatty acid metabolism. GW501516 activates PPARδ receptors, increases lipoprotein lipase and apolipoproteins in the liver, thereby reducing low-density lipoprotein (LDL), reducing the level of triglycerides in the blood, releasing fatty acids that oxidize fat cells, that is Everyone is talking about burning fat. In addition, when the PPARδ receptor is activated, high-density lipoprotein (HDL) in the liver increases, and the increase in high-density lipoprotein (HDL) can transport blood lipids in the blood to the liver for metabolism. Overall, GW501516, as a PPARδ receptor agonist, can increase high-density lipoprotein (HDL) and reduce low-density lipoprotein (LDL) to increase the rate of fat loss and improve cholesterol status in the body.
|
my account
